Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer

被引：0
|
作者：
Perez, E. [1 ]
Lopez-Vega, J. M. [2 ]
Petit, T. [3 ,4 ]
Zamagni, C. [5 ]
Freudensprung, U. [6 ]
Bastiere-Truchot, L. [7 ]
Walker, R. [7 ]
Andersson, M. [8 ]
机构：
[1] Mayo Clin, Div Hematol Oncol, Jacksonville, FL USA
[2] Hosp Univ Marques de Valdecilla, Dept Med Oncol, Santander, Spain
[3] Paul Strauss Canc Ctr, Strasbourg, France
[4] Univ Strasbourg, Dept Med Oncol, Strasbourg, France
[5] Policlin S Orsola Malpighi Hosp, Med Oncol Unit, Bologna, Italy
[6] Stamford Consultants AG, Basel, Switzerland
[7] Roche, Basel, Switzerland
[8] Rigshosp, Dept Oncol, Copenhagen, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S178 / S179
页数：2
相关论文
共 50 条
  • [21] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Nigel Fleeman
    Adrian Bagust
    Sophie Beale
    Kerry Dwan
    Rumona Dickson
    Chris Proudlove
    Yenal Dundar
    [J]. PharmacoEconomics, 2015, 33 : 13 - 23
  • [22] Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
    Fleeman, Nigel
    Bagust, Adrian
    Beale, Sophie
    Dwan, Kerry
    Dickson, Rumona
    Proudlove, Chris
    Dundar, Yenal
    [J]. PHARMACOECONOMICS, 2015, 33 (01) : 13 - 23
  • [23] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [24] Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE)
    Bachelot, T.
    Puglisi, F.
    Ciruelos, E.
    Peretz-Yablonski, T.
    Schneeweiss, A.
    Easton, V.
    Lindegger, N.
    Restuccia, E.
    Miles, D.
    [J]. CANCER RESEARCH, 2017, 77
  • [25] Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
    Bachelot, T.
    Ciruelos, E.
    Schneeweiss, A.
    Puglisi, F.
    Peretz-Yablonski, T.
    Bondarenko, I.
    Paluch-Shimon, S.
    Wardley, A.
    Merot, J. -L.
    du Toit, Y.
    Easton, V.
    Lindegger, N.
    Miles, D.
    Bouzid, Kamel
    Campone, Mario
    Coudert, Bruno
    Nowecki, Zbigniew
    Errihani, Hassan
    Dalenc, Florence
    Ferreira, Ana
    Mano, Max
    Ricci, Francesco
    Kalofonos, Haralabos
    Andreetta, Claudia
    Montemurro, Filippo
    Barrett, Sophie
    Zhang, Qingyuan
    Mavroudis, Dimitris
    Matus, Juan
    Beato, Carlos
    Hu, Xichun
    Gaafar, Rabab
    Azeem, Hamdy Abdel
    Perrin, Christophe
    Ettl, Johannes
    Lang, Istvan
    Verma, Sunil
    Li, Huiping
    Brain, Etienne
    Hoffmann, Oliver
    Cariello, Anna
    Tondini, Carlo
    Altwegeiri, Taher
    Loman, Niklas
    Lux, Michael
    Frassoldati, Antonio
    Aziz, Zeba
    Salas, Fernando
    Streb, Joanna
    Wronski, Andrzej
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (05) : 766 - 773
  • [26] Cardiac safety of trastuzumab in combination with epirubicin/cyclophosphamide as first-line therapy in patients with HER2-positive metastatic breast cancer
    Untch, M.
    Tjulandin, S.
    Jonat, W.
    Meerpohl, H.
    Lichinitser, M.
    Manikhas, G. M.
    Jaenicke, F.
    Muscholl, M.
    Pauschinger, M.
    Lehle, M.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 216 - 216
  • [27] Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Dias, Zetina L.
    Gaui, M.
    Otero Reyes, D.
    Jassem, J.
    Button, P.
    Bell, R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [28] Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)
    Chan, A.
    Yamamoto, D.
    Bell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Noninterventional study HELENA - Advanced (metastatic or locally recurrent, inoperable) HER2-positive breast cancer: First-Line trEatmeNt with pertuzumAb after adjuvant trastuzumab therapy
    Thill, Marc
    Ziegler-Loehr, Katja
    Wagner, Harald
    Helling-Giese, Gertrud
    Greinemann, Jasmin
    Schmalhofer, Otto
    Reichert, Dietmar
    [J]. CANCER RESEARCH, 2015, 75
  • [30] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
12345